Annual report pursuant to Section 13 and 15(d)

Development Award - Additional Information (Detail)

v3.3.1.900
Development Award - Additional Information (Detail)
 1 Months Ended 3 Months Ended
Apr. 20, 2015
USD ($)
Installment
May. 31, 2015
USD ($)
Dec. 31, 2015
USD ($)
Development Award [Line Items]      
Deferred revenue   $ 1,250,000  
Resunab [Member]      
Development Award [Line Items]      
Percentage of royalty over receivables under agreement 500.00%    
Number of installments | Installment 3    
Payment due period after the first commercial sale 90 days    
Royalty payment, sales target $ 500,000,000    
Resunab [Member] | Upon Transfer Sale or Licensing [Member]      
Development Award [Line Items]      
Royalty payable 15,000,000    
CFFT [Member]      
Development Award [Line Items]      
Amount received upon execution of award agreement     $ 1,250,000
CFFT [Member] | Resunab [Member]      
Development Award [Line Items]      
Amount received upon execution of award agreement   $ 1,250,000 1,250,000
Deferred revenue     2,500,000
Remaining amount receivable upon achievement of certain milestones     $ 2,500,000
Maximum [Member] | Resunab [Member]      
Development Award [Line Items]      
Development award received 5,000,000    
Maximum [Member] | Resunab [Member] | Upon Commercialization of the Product [Member]      
Development Award [Line Items]      
Royalty payable 25,000,000    
Maximum [Member] | Resunab [Member] | Upon Reaching the Sales Target [Member]      
Development Award [Line Items]      
Royalty payable $ 5,000,000